Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Positive results in recent animal study strongly support first-ever human investigation for DehydraTECH-liraglutide

DehydraTECH-processed tirzepatide from Zepbound(R) is being tested in an oral dose format

World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules

DehydraTECH clinical test article manufacturing has been completed

DehydraTECH(TM) for GLP-1 being optimized for global pharmaceutical use

DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups

DehydraTECH-processed Tirzepatide From Zepbound(R) is Being Tested in an Oral Dose Format

First-ever DehydraTECH-processed tirzepatide from Zepbound(R) to be tested in a swallowed oral format

Outgoing CEO, Chris Bunka, to remain on as Chairman of the Board of Directors and Executive Strategic Advisor

- Absorption improvements appear to continue with DehydraTECH-processed Rybelsus(R) vs. Rybelsus(R) tablets even under "fed" conditions
- DehydraTECH-treated Rybelsus(R) does absorb through a mouth-melt product format